Scientists at The Scripps Research Institute (TSRI) have identified key triggers of an important cancer-blocking mechanism in cells. Termed "oncogene-induced senescence," this mechanism can block most cancer types, and is commonly experienced when incipient skin cancers turn instead into...
Re-routing anti-cancer drugs to the "power plants" that make energy to keep cells alive is a promising but long-neglected approach to preventing emergence of the drug-resistant forms of cancer - source of a serious medical problem, scientists are reporting. That's the conclusion of a new study...
Researchers from the Research Programme in Biomedical Informatics (GRIB) from the IMIM (Hospital del Mar Research Institute) and the Pompeu Fabra University (UPF) have identified 115 proteins in silico (via computer simulation) that could be highly relevant to treat colon-rectal cancer, since...
There's no need to recall the litany of criticisms aimed at Philadelphia sports fan; cheering injured players and snowballs at Santa have long passed the point of cliché.
The fact is that Philly fans will never get a break because of that perception. For example, if a few of them boo images of...
Broccoli can significantly reduce your risk of developing cancers if you don't destroy the enzyme myrosinase - you can only do this effectively by steaming the vegetable lightly. Overcook it and the health benefits will be considerably undermined, researchers from the University of Illinois...
Analyses at 62 months, or more than two years after treatment completion, confirm and extend the durable clinical and anticancer benefits of the bisphosphonate zoledronic acid that were reported at the 48-month follow-up in the Austrian Breast and Colorectal Cancer Study Group Trial 12...
Zoledronic acid improves survival in multiple myeloma patients versus the UK and European standard treatment of clodronic acid (sodium clodronate) in patients with multiple myeloma. Since overall survival in patients given zoledronic acid improved independently of prevention of skeletal-related...
Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing potential best in class oncology and central nervous system (CNS) therapeutics, today announced that it will present pre-clinical data on its anticancer compound RX-8243 at the American Association...
Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing potential best in class oncology and central nervous system (CNS) therapeutics, today announced that it will present pre-clinical data on its anticancer compound RX-8243 at the American Association...
Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing potential best in class oncology and central nervous system (CNS) therapeutics, today announced that it will present pre-clinical data on its anticancer compound RX-8243 at the American Association...